Sign In
Buy DYN
$17.99
+0.750 (+4.35%)
At Close: Jun 03, 2026
Dyne Therapeutics: FORCE Platform Poised To Revolutionize Gene Therapy
10:02pm, Saturday, 27'th May 2023
Dyne Therapeutics, Inc. has announced that its investigational therapeutic, DYNE-251, for Duchenne muscular dystrophy (DMD), has been granted FDA orphan drug and rare pediatric disease designations. D
Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
07:35am, Wednesday, 03'rd May 2023
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peopl
Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS
04:46pm, Tuesday, 02'nd May 2023
- FORCE Delivers to CNS in Non-Human Primates - - FORCE Achieves Robust Reduction of Toxic Nuclear DMPK RNA and Foci in Brain of a DM1 Disease Model -
Dyne Therapeutics to Present at Upcoming Investor Conferences
07:30am, Tuesday, 07'th Mar 2023
WALTHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo
Diving Into Dyne Therapeutics
05:01pm, Thursday, 19'th Jan 2023
Shares of genetic muscle disease concern Dyne Therapeutics, Inc. have enjoyed a recent bounce on the back of good news from a rival, more than tripling in price. The recent news somewhat validated/de-
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
10:33am, Wednesday, 18'th Jan 2023
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
All You Need to Know About Dyne Therapeutics, Inc. (DYN) Rating Upgrade to Strong Buy
01:32pm, Tuesday, 10'th Jan 2023
Dyne Therapeutics, Inc. (DYN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
07:30am, Tuesday, 03'rd Jan 2023
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop
Here's Why Dyne Therapeutics, Inc. (DYN) Is a Great 'Buy the Bottom' Stock Now
11:17am, Friday, 09'th Dec 2022
Dyne Therapeutics, Inc. (DYN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreeme
Dyne Therapeutics to Present at Investor Conferences in November
07:30am, Wednesday, 02'nd Nov 2022
WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop
Dyne Therapeutics to Present at Chardan's 6th Annual Genetic Medicines Conference
07:30am, Tuesday, 27'th Sep 2022
WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo
Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
04:30pm, Tuesday, 06'th Sep 2022
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo
Chardan Initiates Coverage On These 'Intriguing Small-Cap Stories"
04:07pm, Wednesday, 20'th Jul 2022
Chardan Research initiated coverage on Avidity Biosciences Inc (NASDAQ: RNA) with a Buy rating and a price target of $29 and Dyne Therapeutics Inc (NASDAQ: DYN) with a Buy rating and a price t
What's Going On With Dyne Therapeutics Shares Today?
10:24am, Tuesday, 05'th Jul 2022
Dyne Therapeutics Inc (NASDAQ: DYN) shares are trading lower by 5.42% to $6.81 after the company announced FDA clearance of its Investigational New Drug application for DYNE-251 for the treatment of
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
07:30am, Friday, 03'rd Jun 2022
WALTHAM, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with
